

Don't wait, MEDICATE!



CARDALIS™ is the safe, FDA-approved, once-a-day, **unique combination for the management of congestive heart failure (CHF) in dogs.** It includes half of the recommended quad therapy once CHF occurs.



Safe¹



Effective¹



Increases Compliance

Body Weight	5.5 - 10.9 lbs 2.5 - 5 kg	11 - 21.9 lbs 5 - 10 kg	22 - 43.9 lbs 10 - 20 kg	44 - 87.9 lbs 20 - 40 kg	88 - 131.9 lbs 40 - 60 kg	132 - 176 lbs 60 - 80 kg
CARDALIS™ 20/2.5 20 mg Spironolactone 2.5 mg Benazepril HCl						
CARDALIS™ 40/5 40 mg Spironolactone 5 mg Benazepril HCl						
CARDALIS™ 80/10 80 mg Spironolactone 10 mg Benazepril HCl						

See accompanying **product insert** for more information.

¹ Coffman M, Guillot E, Blondel T, et al. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone Study (BESST). J Vet Intern Med. 2021;35(4):1673-1687. doi:10.1111/jvim.16155. Approved with concurrent therapy (e.g. furosemide) for mild, moderate and severe congestive heart failure in dogs. Important Safety Information: Do not administer in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) in dogs with renal insufficiency. Do not use in dogs with hypoadrenocorticism (Addison's disease), hyperkalemia or hyponatremia. Do not use in dogs with known hypersensitivity to ACE inhibitors or spironolactone. The safety and effectiveness of concurrent therapy of CARDALIS™ with pimobendan has not been evaluated. The safety of CARDALIS™ has not been evaluated in pregnant, lactating, breeding, or growing dogs. CARDALIS™ administration should begin after pulmonary edema is stabilized. Regular monitoring of renal function and serum potassium levels is recommended. Common side effects from a field study include anorexia, vomiting, lethargy, diarrhea, and renal insufficiency. For full prescribing information, visit www.cardalis.com. CRD-104-23v2

